Enlivex Therapeutics Ltd Stock
Enlivex Therapeutics Ltd Stock price
Key metrics
| Market capitalization | $19.53m |
| Enterprise Value | $-3.55m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.27 |
| P/B ratio (TTM) P/B ratio | 0.89 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-15.54m |
| Free Cash Flow (TTM) Free Cash Flow | $-13.11m |
| Cash position | $23.61m |
Is Enlivex Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
Enlivex Therapeutics Ltd Stock Analysis
Analyst Opinions
2 Analysts have issued a Enlivex Therapeutics Ltd forecast:
Analyst Opinions
2 Analysts have issued a Enlivex Therapeutics Ltd forecast:
Financial data from Enlivex Therapeutics Ltd
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.55 -0.55 |
35%
35%
|
|
| EBITDA | -15 -15 |
20%
20%
|
EBIT (Operating Income) EBIT | -16 -16 |
20%
20%
|
| Net Profit | -15 -15 |
48%
48%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Enlivex Therapeutics Ltd directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Enlivex Therapeutics Ltd Stock News
Company Profile
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.
| Head office | Israel |
| CEO | Oren Hershkovitz |
| Founded | 2012 |
| Website | www.enlivex.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
